Relapsing-remitting Multiple Sclerosis Treated with Interferon Beta-1a 44 μg from the Onset - a Case Report

被引:0
|
作者
Kurkova, B. [1 ]
Hradilek, P. [1 ]
机构
[1] FN Ostrava, Neurol Klin, Ostrava 70852, Czech Republic
关键词
relapsing-remitting multiple sclerosis; disease modifying drugs; interferon beta-1a;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
As per its globally accepted definition, the cerebrospinal multiple sclerosis is characterized by its dissemination in space and time. Being the most frequent neurological cause of disability in young people of productive age, early treatment initiation is crucial. Here we present a case report of a male patient diagnosed with the multiple sclerosis at 26 years of age. He experienced two relapses during the 24 months since the diagnosis and was indicated for interferon beta-1a treatment. The treatment has been well-tolerated with a minimum of side effects that respond well to symptomatic treatment. Throughout the seven years of treatment, he experienced just one mild relapse without any effect on his ability to work or any restriction to his activities of daily living.
引用
下载
收藏
页码:32 / 34
页数:3
相关论文
共 50 条
  • [21] PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Gitlin, M.
    Snyder, S.
    Jhaveri, M.
    VALUE IN HEALTH, 2019, 22 : S746 - S746
  • [22] PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Gitlin, M.
    Snyder, S.
    Jhaveri, M.
    VALUE IN HEALTH, 2019, 22 : S744 - S744
  • [23] Influence of histocompatibility genes on disease susceptibility and treatment response in patients with relapsing-remitting multiple sclerosis treated with interferon beta-1a
    Flechter, Shlomo
    Klein, Tirza
    Pollak, Lea
    NEUROLOGY INTERNATIONAL, 2011, 3 (01) : 17 - 21
  • [24] Efficacy and safety of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis: Further outcomes from the IMPROVE study
    De Stefano, Nicola
    Sormani, Maria Pia
    Stubinski, Bettina
    Blevins, Gregg
    Drulovic, Jelena S.
    Issard, Delphine
    Shotekov, Penko
    Gasperini, Claudio
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2012, 312 (1-2) : 97 - 101
  • [25] Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing-remitting multiple sclerosis: A retrospective analysis
    Fisher, E.
    Nakamura, K.
    Lee, J-C
    You, X.
    Sperling, B.
    Rudick, R. A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (05) : 668 - 676
  • [26] Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
    Liu, Ying
    Vollmer, Timothy
    Havrdova, Eva
    Riester, Katherine
    Lee, Andrew
    Phillips, Glenn
    Wang, Ping
    Sabatella, Guido
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 11 : 18 - 24
  • [27] Health economic evaluation of interferon beta-1a versus interferon beta-1b for patients with relapsing-remitting multiple sclerosis in Switzerland
    Nuijten, M. J. C.
    Chofflon, M.
    MULTIPLE SCLEROSIS, 2007, 13 : S262 - S262
  • [28] Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
    Zhang, Jian
    Shi, Shengliang
    Zhang, Yueling
    Luo, Jiefeng
    Xiao, Yousheng
    Meng, Lian
    Yang, Xiaobo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [29] Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Sheridan M. Hoy
    CNS Drugs, 2015, 29 : 171 - 179
  • [30] Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Hoy, Sheridan M.
    CNS DRUGS, 2015, 29 (02) : 171 - 179